LDK378 compound well-tolerated in patients with ALK+ NSCLC
23:25 EDT 1 Jun 2012 | The Medical News
A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib-the only approve..
Original Article: LDK378 compound well-tolerated in patients with ALK+ NSCLC
More From BioPortfolio on "LDK378 compound well-tolerated in patients with ALK+ NSCLC"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
